[Treatment of S-1 plus weekly CDDP for advanced gastric cancer].

Takeshi Kemmochi; Tomohisa Egawa; Yasunori Mihara; Tomoyuki Irino; Yasuhiro Ito; Atsushi Nagashima; Hiroyuki Makino; Wataru Yamamuro

[Treatment of S-1 plus weekly CDDP for advanced gastric cancer].

Takeshi Kemmochi, Tomohisa Egawa, Yasunori Mihara, Tomoyuki Irino, Yasuhiro Ito, Atsushi Nagashima, Hiroyuki Makino, Wataru Yamamuro

Research output: Contribution to journal › Article › peer-review

Abstract

We analyzed the clinical efficacy and safety of chemotherapy using S-1 plus weekly CDDP( w-CS therapy) for unresectable gastric cancer. Twenty one patients were treated with this treatment. S-1 80 mg/m²/day was administered for 2 weeks followed by a 1-week rest. CDDP 20 mg/m² was injected intravenously on day 1 and 8. The overall response rate was 52. 3%. The disease control rate was 85.7%. Grade 3 or 4 major toxicity comprised neutropenia (14.2%), thrombocytopenia (4.7%) and plasma creatinine elevation (4.7%). w-CS therapy is satisfied resulting with efficacy and safety. Thus, future clinical trials and accumulation of futher cases are warranted.

Original language	English
Pages (from-to)	2351-2353
Number of pages	3
Journal	Gan to kagaku ryoho. Cancer & chemotherapy
Volume	38
Issue number	12
Publication status	Published - 2011 Nov
Externally published	Yes

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{a62d09f60a15443ab748f020db1d7f15,

title = "[Treatment of S-1 plus weekly CDDP for advanced gastric cancer].",

abstract = "We analyzed the clinical efficacy and safety of chemotherapy using S-1 plus weekly CDDP( w-CS therapy) for unresectable gastric cancer. Twenty one patients were treated with this treatment. S-1 80 mg/m2/day was administered for 2 weeks followed by a 1-week rest. CDDP 20 mg/m2 was injected intravenously on day 1 and 8. The overall response rate was 52. 3%. The disease control rate was 85.7%. Grade 3 or 4 major toxicity comprised neutropenia (14.2%), thrombocytopenia (4.7%) and plasma creatinine elevation (4.7%). w-CS therapy is satisfied resulting with efficacy and safety. Thus, future clinical trials and accumulation of futher cases are warranted.",

author = "Takeshi Kemmochi and Tomohisa Egawa and Yasunori Mihara and Tomoyuki Irino and Yasuhiro Ito and Atsushi Nagashima and Hiroyuki Makino and Wataru Yamamuro",

year = "2011",

month = nov,

language = "English",

volume = "38",

pages = "2351--2353",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "12",

}

TY - JOUR

T1 - [Treatment of S-1 plus weekly CDDP for advanced gastric cancer].

AU - Kemmochi, Takeshi

AU - Egawa, Tomohisa

AU - Mihara, Yasunori

AU - Irino, Tomoyuki

AU - Ito, Yasuhiro

AU - Nagashima, Atsushi

AU - Makino, Hiroyuki

AU - Yamamuro, Wataru

PY - 2011/11

Y1 - 2011/11

N2 - We analyzed the clinical efficacy and safety of chemotherapy using S-1 plus weekly CDDP( w-CS therapy) for unresectable gastric cancer. Twenty one patients were treated with this treatment. S-1 80 mg/m2/day was administered for 2 weeks followed by a 1-week rest. CDDP 20 mg/m2 was injected intravenously on day 1 and 8. The overall response rate was 52. 3%. The disease control rate was 85.7%. Grade 3 or 4 major toxicity comprised neutropenia (14.2%), thrombocytopenia (4.7%) and plasma creatinine elevation (4.7%). w-CS therapy is satisfied resulting with efficacy and safety. Thus, future clinical trials and accumulation of futher cases are warranted.

AB - We analyzed the clinical efficacy and safety of chemotherapy using S-1 plus weekly CDDP( w-CS therapy) for unresectable gastric cancer. Twenty one patients were treated with this treatment. S-1 80 mg/m2/day was administered for 2 weeks followed by a 1-week rest. CDDP 20 mg/m2 was injected intravenously on day 1 and 8. The overall response rate was 52. 3%. The disease control rate was 85.7%. Grade 3 or 4 major toxicity comprised neutropenia (14.2%), thrombocytopenia (4.7%) and plasma creatinine elevation (4.7%). w-CS therapy is satisfied resulting with efficacy and safety. Thus, future clinical trials and accumulation of futher cases are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84858830425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858830425&partnerID=8YFLogxK

M3 - Article

C2 - 22202379

AN - SCOPUS:84858830425

VL - 38

SP - 2351

EP - 2353

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 12

ER -

[Treatment of S-1 plus weekly CDDP for advanced gastric cancer].

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this